A posting yesterday in PRNewswire tells of a collaborative research effort called “Newborn Possibilities Program” in Tuscon, Arizona, for preservation of cord blood stem cells “so that if a child is diagnosed with the condition, he or she may be eligible to receive a new treatment being researched under approval from the FDA using the child’s own cord blood stem cells.”
This research initiative is being done as a collaborative effort by the Cord Blood Registry, the world’s largest stem cell bank; Save the Cord Foundation, a nonprofit advocacy organization based in Tucson; Tucson Medical Center, the region’s leading birthing hospital; and Watching Over Mothers and Babies Foundation (WOMB), a local non-profit research foundation.
A statement by the CEO of the Cord Blood Registry, Tom Moore, best describes the goal of this new program:
This program is a way for us to provide a safety net to children at-risk for cerebral palsy and other forms of neonatal brain injury while helping to advance the science of regenerative medicine. CBR and our collaborators in this unique program share a commitment to advance cord blood stem cell research, expand education about the value of cord blood banking, and improve outcomes for children with neurological disabilities.
In a statement by the founders of one of the program’s collaborating members, Save the Cord Foundation, Anne Sarabia and Charis Ober, we are provided further insight into the present and future goals of the program:
We believe that cord blood will play a very important role in future medicine and will benefit so many children in our community at risk for cerebral palsy. Our dream is that this program will inspire other medical institutions to follow and make preserving cord blood the standard of care for all newborns.
The Newborn Possibilities Program is laying the groundwork for potential new treatment options for cerebral palsy and neurological disorders by connecting patients who may be at risk for these conditions and who have access to their cord blood stem cells with FDA-approved research studies. We believe this program will be instrumental in accelerating the pace of research and potentially helping many children.
As those of you who follow our blog postings and/or the recent news concerning stem cell research relating to cerebral palsy are aware, the Food and Drug Administration recently approved a human clinical trial evaluating the safety and efficacy of using a child’s own newborn blood stem cells to treat cerebral palsy.
Having been involved in handling cases of children with cerebral palsy for many years, I have seen the issues of preservation of tissue, blood and medical records (i.e. fetal monitor strips) go the full gamut. For years, placental pathologists were begging medical institutions to preserve placentas for further research into perinatal birth injuries (among other concerns). There was a time when one institution, which shall remain nameless, had a suspected policy of discarding fetal monitor strips (gee – wonder why that was!) and so on and so on. It is really heartening to see that this new collaborative program is putting the interests of science, children’s health and knowledge far ahead of any conjured concerns relating to fear of litigation. Hopefully, this program, in conjunction with all the other research regarding cerebral palsy now going on, will get to the bottom of this horrible disorder and provide new meaningful care options for at least some of the victims of cerebral palsy.